pMMR

Merck and Eisai announced five-year follow-up data from the Phase 3 KEYNOTE-775/Study 309 trial, demonstrating a sustained survival benefit of KEYTRUDA plus LENVIMA compared to chemotherapy in patients with advanced endometrial carcinoma. For pMMR patients, the five-year OS rate was 16.7% for the combination versus 7.3% for chemotherapy. These long-term results offer a promising treatment option for this aggressive cancer, despite the associated adverse events. The combination is approved in the U.S., EU, and Japan for specific patients.